Abstract
Infection by human immunodeficiency virus type 1 (HIV-1) is associated with cellular activation and expression of the interleukin-2 (IL-2) receptor. A genetically engineered fusion toxin, DAB486 IL-2, that contains the enzymatic site and translocation domain of diphtheria toxin and the receptor binding domain of IL-2 specifically kills cells that express high-affinity IL-2 receptors. This toxin selectively eliminated the HIV-1-infected cells from mixed cultures of infected and uninfected cells and inhibited production of viral proteins and infectious virus. Thus, cellular activation antigens present a target for early antiviral intervention.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Cell Survival
-
Diphtheria Toxin / administration & dosage*
-
Diphtheria Toxin / genetics
-
Gene Products, env / metabolism
-
Gene Products, gag / metabolism
-
HIV Core Protein p24
-
HIV Envelope Protein gp160
-
HIV Infections / therapy*
-
HIV-1 / metabolism
-
Humans
-
In Vitro Techniques
-
Interleukin-2 / genetics
-
Interleukin-2 / metabolism
-
Protein Precursors / metabolism
-
Receptors, Interleukin-2 / physiology*
-
Recombinant Fusion Proteins / toxicity
-
T-Lymphocytes / cytology
-
T-Lymphocytes / microbiology*
-
Viral Core Proteins / metabolism
Substances
-
Diphtheria Toxin
-
Gene Products, env
-
Gene Products, gag
-
HIV Core Protein p24
-
HIV Envelope Protein gp160
-
Interleukin-2
-
Protein Precursors
-
Receptors, Interleukin-2
-
Recombinant Fusion Proteins
-
Viral Core Proteins
-
p55 gag precursor protein, Human immunodeficiency virus 1